GlassScriptPhysician profile
Rubal Sharma
NPI 1689163602
$1,474.56
in general payments reported to CMS, 2019-2025
33 companies · $1,136 in 2025
The $1,136 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $339 · 2025: $1,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,310.69 |
| Education | $163.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $135.00 | 2025 | Rytelo |
| Novartis Pharmaceuticals Corporation | $132.57 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $126.33 | 2024-2025 | Onivyde |
| Adc Therapeutics America, INC. | $124.74 | 2025 | |
| Pfizer INC. | $81.40 | 2024-2025 | |
| Incyte Corporation | $76.19 | 2024-2025 | Jakafi, Niktimvo |
| Merck Sharp & Dohme LLC | $73.43 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $65.73 | 2024-2025 | Iclusig, Fruzaqla |
| Daiichi Sankyo INC. | $59.26 | 2025 | Enhertu, Vanflyta |
| Sumitomo Pharma America, INC. | $53.90 | 2025 | Orgovyx |
| Abbvie INC. | $48.85 | 2025 | |
| Janssen Biotech, INC. | $41.12 | 2024 | Rybrevant |
| Glaxosmithkline, LLC. | $39.67 | 2024-2025 | Blenrep, Ojjaara |
| Exelixis INC. | $39.47 | 2025 | Cabometyx |
| Pharmaessentia USA Corporation | $36.55 | 2024 | Besremi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $29.44 | 2024 | Aquamantys(Tm) |
| Astrazeneca Pharmaceuticals LP | $26.48 | 2025 | |
| Tempus Ai, INC | $22.97 | 2024 | |
| Pharmacosmos Therapeutics INC. | $21.86 | 2024 | Monoferric |
| Eisai INC. | $21.36 | 2025 | |
| Stemline Therapeutics INC. | $21.35 | 2025 | Orserdu |
| Novocure INC. | $21.15 | 2025 | Optune Lua (Novottf-200t) |
| Kite Pharma, INC. | $18.92 | 2025 | Yescarta |
| Myriad Genetic Laboratories, INC. | $18.67 | 2024 | Precisetumor |
| Beone Medicines USA, INC. | $18.32 | 2025 | Brukinsa |
| Astellas Pharma US INC | $16.64 | 2025 | Xtandi |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Janssen Pharmaceuticals, INC | $15.99 | 2025 | |
| Aveo Pharmaceuticals, INC. | $15.04 | 2025 | |
| Emd Serono, INC. | $14.86 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.04 | 2025 | |
| Sun Pharmaceutical Industries INC. | $13.75 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $13.52 | 2025 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rubal Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.